More than 25 years of professional experience as Board member of companies such as Medigene AG, Shield Therapeutics plc, WILEX AG, Immunocore ltd. and Catherex Inc. as well as Advisory roles in companies to execute exit strategies .Peter joined APEIRON Biologics in 2017 and is founding president of BIOTECH AUSTRIA, the Austrian Biotechnology Association.
Andreas Gerber, PhD, has multiple years of experience in the pharmaceutical industry.
Before joining APEIRON Biologics, he served as Site Head & Executive Director Biologics
and Vaccines Formulation at Merck Sharpe & Dohme. Previously, he was responsible for
the development of various active pharmaceutical ingredients and their production at
Novartis Austria and managed a production site for biologics in Kundl, Austria. Andreas
received his PhD from the University of Basel and an Executive MBA from the University of St. Gallen.
Romana Gugenberger holds a PhD in Molecular Biology from the University of Vienna and worked several years at the Medical University of Vienna in the field of Cardiovascular Research and Tumor Biology. Since 11 years she works at APEIRON Biologics and supports non-clinical and clinical projects. At the moment she is leading the APN401 – APEIRON´s autologous cellular therapy.
Entrepreneur, investor, business angel ("Austrian Business Angel of the Year 2009"), and Senior Adviser to renowned global institutions (e.g. UBS Investment Bank, World Economic Forum). More than 20 years of experience in international strategic consulting as Senior Managing Partner at Roland Berger, heading Austria and Eastern Europe for more than 15 years. European Program Manager for a Computer Line at Hewlett Packard. Lecturer in Vienna respectively Munich on "Corporate Governance", "China", and "Globalization".
Austrian physician and politician. Studied Medicine and Business Administration in Vienna. Referee for ecology of the Medical Association of Austria. Member of Austrian National Assembly from 1994 until 2017.
Independent consultant with currently 40 employees focusing on global drug development and regulatory affairs with special considerations for orphan drugs. Ulrich Granzer has major experience with biotech products and small molecules including orphan products.
He holds a PhD in pharmaceutical chemistry. Prior to being independent he held senior positions at Glaxo, BASF pharma Knoll, and Bayer.
He has a track record of working on more than 300 new molecular entities (small molecules, proteins incl. antibodies, oligonucleotides, gene therapies, cell therapies).
Dr. Schuehsler led the creation of TVM Capital Healthcare in the United Arab Emirates in 2009, and in Singapore 2018, after he had joined the TVM Capital group of companies in Munich in 1990. Helmut has raised more than US$1bn in committed capital from more than 50 international investors, has overseen more than 120 investments in the health and life science market, and more than 50 IPOs and 30 M&A exit transactions.
A rounded finance professional, spending the first twenty years in banking where he was responsible for several derivatives trading books and then ran the European structured finance departments at J P Morgan, Credit Suisse and Bank of America. He has, in the last fifteen years, founded multiple financial businesses; including in the asset management, financial advisory and insurance underwriting arenas. For the last twenty years he has been a keen Private Equity investor in both the biotech and fintech industries and the Treasurer of Docklands Outreach, a London based charity. He holds a Masters from University College, Oxford in Politics, Philosophy and Economics and a Masters in Modern and Contemporary Literature from Birkbeck College, London.
Founder of Apeiron. Studied Medicine & Arts at the University Innsbruck, since 1990 worked as post-doctoral fellow at the Ontario Cancer Institute. Author of more than 400 publications and patents; ranked twice among top 10 most cited scientists globally. Worked for 13 years with Amgen, the Ontario Cancer Institute and University of Toronto. Former Scientific Director of the IMBA in Vienna (2002 until 2018), now Scientific Director and Professor of the Life Science Institute of the University of British Columbia.
Scientist, Keenan Research Centre for Biomedical Science, St. Michael’s Hospital; Keenan Chair in Medicine, St. Michael’s Hospital; Professor, Departments of Medicine, Biomedical Engineering and Surgery, University of Toronto; Chair, Clinical Trials Ontario
Is an Austrian haematologist, oncologist and immunologist with the main focus of research on tumour defence and stem cell transplantation. From 1990 until his retirement in 2009 he was director of the III Medical Clinic and Polyclinic at the University Medical School of the Johannes Gutenberg University Mainz. He founded Ganymed Pharmaceuticals in 2001 and with Uğur Şahin BioNTech. He was also involved in the establishment of the Institute for Translational Oncology (TRON) at the University Medical Center Mainz. Christoph has been President of the Association for Cancer Immunotherapy (CIMT) for many years and is the author of more than 200 scientific publications.
Reed and Carolee Walker Professor of Pediatrics, Human Oncology, and Genetics; Director of Research, UW Division of Pediatric Hematology, Oncology and BMT, UW Carbone Cancer Center and American Family Children’s Hospital
University of Wisconsin
Thomas has more than 15 years of experience in academic research (molecular biology and immunology), clinical practice (dermatology, clinical immunology and immune-oncology) and clinical development in the biopharmaceutical industry. He has worked in the biopharmaceutical industry for almost 15 years, holding positions in oncology drug development and medical affairs, encompassing assignments in Germany, Europe and at a global level.